1. Background {#sec78290}
=============

*Pseudomonas aeruginosa* is an obligate aerobic Gram-negative bacillus, the natural flora of the skin and gastrointestinal tract of humans which can be found in water and soil ([@A13783R1]). This bacterium is an opportunistic pathogen and a major cause of nosocomial infections in immunocompromised patients, including patients with a wide range of malignancies, cystic fibrosis, burns, etc. This bacterium comprises a variety of pathogens and has a high resistance to most common antibiotics ([@A13783R2], [@A13783R3]).

One of the most prominent attributes of these strains is their resistance to multiple clinically important antibiotics like third generation of cephalosporins, imipenem and aztreonam. A great number of *P. aeruginosa* strains generate various classes of extended spectrum β-lactamases (ESBLs) which allow the bacterium to tolerate against extended--spectrum cephalosporins, such as cefotaxime, ceftriaxone and ceftazidime and they have been reported with a developing frequency ([@A13783R4]). Conventionally, ESBLs have been derivatives of TEM and SHV parent enzymes. Although, an explosion of developments in ESBLs of non-TEM, non-SHV lineage was seen in Europe last year. Notably, the CTX-M type ESBLs have become widespread ([@A13783R5]).

ESBLs are undergoing continuum mutations, causing the progression of new enzymes, showing expanded substrate profiles. So far, there have been more than 300 different ESBL variants which have been clustered into nine different structural and evolutionary families based on their amino acid sequences. TEM and SHV were the major types. Nevertheless, CTX-M type is more frequent in some countries ([@A13783R6]). PER-1 that can hydrolyze penicillins, oxyimino-cephalosporins and aztreonam, but not oxacillins, cephamycins and carbapenems, was first detected on a plasmid of *P*.*aeruginosa* RNL-1 in France in 1991 ([@A13783R7]).

In 1996, VEB-1 enzyme was first identified in an *Escherichia coli* isolate from Vietnam with four further sequence variants since detected in widely scattered countries, in members of the *Enterobacteriaceae* or in the nonfermenting genera, particularly *Pseudomonas spp*. ([@A13783R8]). Detection of TEM and SHV genes by molecular methods in ESBL-producing bacteria and their pattern of antimicrobial resistance can provide beneficial data about their epidemiology and risk factors associated with these infections ([@A13783R9]).

2. Objectives {#sec78291}
=============

The purpose of this study was to isolate and identify the types of ESBLs produced by *P. aeruginosa* isolated from various specimens (urine, blood, tracheal tube, wound, ear discharge) of patients hospitalized in different units of educational hospitals of Zahedan, Iran.

3. Materials and Methods {#sec78296}
========================

The project was approved by the Zahedan University of Medical Sciences Ethical Committee (No. 2496).

3.1. Bacterial Isolates and Detection of Extended Spectrum β-Lactamases {#sec78295}
-----------------------------------------------------------------------

This descriptive study was performed in Ali-Ebne-Abitaleb and Khatam-e-Anbia Hosbitals in Zahedan, Iran, during one year (2012-2013). *P. aeruginosa* was isolated from patients enrolled in this study. The isolates were cultured on triple sugar iron agar (Merck, Germany) and incubated at 37°C in air. The isolates with positive oxidase test, prepared from a pigment on Mueller--Hinton agar (Merck, Germany) and grown aerobically in OF (Merck, Germany) medium and oxidation of glucose, were identified as *P. aeruginosa*. The organisms were isolated from urine (n = 39), tracheal tube (n = 62), wound (n = 3), blood (n = 10), and ear discharge (n = 2).

Among the 116 collected isolates, 24 (20.9%) were isolated from children. There was 37 (31.9%) female and 79 (68.1%) male. The susceptibilities of the bacterial isolates to eight antimicrobial agents including imipenem (IMI; 10 µg), ciprofloxacin (CIP; 5 µg), ceftazidime (CAZ; 30 µg), ceftriaxone (CRO; 30 µg), cefotaxime (CTX; 30 µg), aztreonam (ATM; 30 µg), piperacillin (PRL; 100 µg) and gentamicin (GM; 10 µg) (Mast, UK) were determined by the disk diffusion method depending on the criteria published by the Clinical and Laboratory Standards Institute (CLSI). *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 were used as controls ([@A13783R10]). Multidrug resistant (MDR) isolates were defined as those resistant to three or more classes of antipseudomonal agents (carbapenems, penicillins, cephalosporins, monobactams, fluoroquinolones and aminoglycosides) ([@A13783R11]).

Minimum inhibitory concentration (MIC) E-test (Liofilchem, Italy) method for cefotaxime (0.002-32 µg), ceftriaxone (0.016-256 µg), ceftazidime (0.016-256 µg) and aztreonam (0.016-256 µg), the recommendations (CLSI) for resistant isolates, was performed and interpreted ([@A13783R10]). ESBL production in all of the isolates was identified by combination disk test (CDT). For each test, disks containing cephalosporin alone (CTX and CAZ) and in combination with clavulanic acid are applied. The inhibition zone around the cephalosporin disk/tablet combined with clavulanic acid is compared with the zone around the disk/tablet with the cephalosporin alone. The test is positive if the inhibition zone diameter is ≥ 5 mm larger with clavulanic acid than without ([@A13783R12]).

### 3.1.2. DNA Extraction and Polymerase Chain Reaction {#sec78292}

ESBL-positive isolates and others showing MICs ≥ 4 μg/mL for CAZ, CTX, CRO and ATM were cultured in LB (Luria Bertani) broth at 37°C overnight and the plasmid DNA was extracted by plasmid isolation kit (MBST, Iran). Specific primers and the annealing temperature for amplifying the blaSHV, blaTEM, blaPER-1, blaCTX-M1 and blaVEB-1 genes by PCR are shown in [Table 1](#tbl19884){ref-type="table"} ([@A13783R13], [@A13783R14]). PCR was carried out by PCR PreMix 20 µL (Bioneer, Korea). *K. pneumoniae* 7881 containing the blaSHV, blaCTX-M and blaTEM genes, *P. aeruginosa* KOAS strain containing the blaPER gene, and *P. aeruginosa* 10.2 containing the blaVEB gene (Pasteur Institute of Iran) were used as controls.

###### Primers Used in This Study

  Primers        Sequence (5´ to 3´)      PCR           Cycles          Gene and Its Size, bp        
  -------------- ------------------------ ------------- --------------- ----------------------- ---- ---------------
  **VEB-1 F**    CGACTTCCATTTCCCGATGC     95°C, 1 min   60°C, 1 min     72°C, 1 min             30   blaVEB643
  **VEB-1 R**    GGACTCTGCAACAAATACGC                                                                
  **PER-1 F**    ATGAATGTCATTATAAAAGC     94°C, 30 s    51.5°C, 1 min   72°C, 1 min             25   blaPER925
  **PER-1 R**    AATTTGGGCTTAGGGCAGAA                                                                
  **TEM F**      GAGTATTCAACATTTCCGTGTC   94°C, 30 s    57°C, 1 min     72°C, 1 min             30   blaTEM861
  **TEM R**      TAATCAGTGAGGCACCTATCTC                                                              
  **SHV F**      AAGATCCACTATCGCCAGCAG    94°C, 30 s    64°C, 1 min     72°C, 1 min             25   blaSHV231
  **SHV R**      ATTCAGTTCCGTTTCCCAGCGG                                                              
  **CTX-m1 F**   GACGATGTCACTGGCTGAGC     94°C, 30 s    56°C, 1 min     72°C, 1 min             25   blaCTX-M1 499
  **CTX-m1 R**   AGCCGCCGACGCTAATACA                                                                 

### 3.1.3. Sequencing of Polymerase Chain Reaction Products {#sec78293}

DNA sequencing for the whole 30 strains was performed with a DNA sequencing kit and analyzed in an automatic DNA sequencer (Bioneer Company, Korea) to determine the detected bla genes, using primers shown in [Table 1](#tbl19884){ref-type="table"}. Homological analyses were performed by BLAST software in GenBank.

### 3.1.4. Statistical Analysis {#sec78294}

Descriptive statistical analyses were performed using SPSS (PASW) version 18 software.

4. Results {#sec78297}
==========

The findings of antimicrobial tests (Kirby Bauer) showed that CIP, PRL and GM were the most efficient antipseudomonal agents. *P. aeruginosa* revealed resistance to CRO (23.3%), CTX (22.4%), IMI (17.2%), CAZ (14.7%), ATM (14.7%), GM (12.1%), PRL (7.8%) and CIP (3.4%), respectively ([Table 2](#tbl19885){ref-type="table"}). Overall, 19 (16.37%) MDR isolates and 8 (6.89%) ESBL-positive isolates were extracted.

###### Antimicrobial Susceptibility Tests on 116 *P. aeruginosa* Isolated From Patients of Two Hospitals in Zahedan, Iran ^[a](#fn17253){ref-type="table-fn"}^

  Antimicrobial Agents, Concentration (µg)   Resistant   Intermediate   Susceptible
  ------------------------------------------ ----------- -------------- -------------
  **Piperacillin, 100**                      9 (7.8)     0 (0)          107 (92.2)
  **Ceftazidime, 30**                        17 (14.7)   0 (0)          99 (85.3)
  **Cefotaxime, 30**                         26 (22.4)   70 (60.3)      20 (17.2)
  **Ceftriaxone, 30**                        27 (23.3)   31 (26.7)      58 (50)
  **Aztreonam, 30**                          17 (14.7)   3 (2.6)        96 (82.8)
  **Imipenem, 10**                           20 (17.2)   3 (2.6)        93 (80.2)
  **Gentamicin, 10**                         14 (12.1)   6 (5.2)        96 (82.8)
  **Ciprofloxacin, 5**                       4 (3.4)     1 (0.9)        111 (95.7)

^a^ Data are presented as No. (%).

Among the MDR isolates, 2 (10.5%) were resistant to 8 antimicrobial agents simultaneously ([Table 3](#tbl19886){ref-type="table"}). The maximum ESBL production was found in blood samples. All the eight ESBL-positive isolates were MDR. Of the 116 isolates, 30 (25.86%) were resistant at least to one of the following antibiotics: CAZ, CRO, CTX and ATM. Among these isolates, 30 (100%), 4 (13.3%), 2 (6.6%), 2 (6.6%), and 0 (0%), amplified the blaTEM, blaVEB-1, blaPER-1, blaSHV, and blaCTX-M1 genes, respectively. From 30 isolates of TEM-positive, 22 isolates were ESBL-negative phenotype.

###### Resistance to Two or More Antimicrobials Among Multidrug Resistant Isolated From Patients of the Two Hospitals in Zahedan, Iran ^[a](#fn17254){ref-type="table-fn"}^

  Resistance to Two or More Antimicrobials    MDR
  ------------------------------------------- -----------
  **CRO, CTX**                                19 (100)
  **CRO, CTX, CAZ**                           17 (89.5)
  **CRO, CTX, CAZ, ATM**                      16 (84.2)
  **CRO, CTX, CAZ, ATM, GM**                  13 (68.4)
  **CRO, CTX, CAZ, ATM, GM, PRL**             8 (42.1)
  **CRO, CTX, CAZ, ATM, GM, PRL, IMI**        4 (21)
  **CRO, CTX, CAZ, ATM, GM, PRL, IMI, CIP**   2 (10.5)

^a^ Data are presented as No. (%).

Furthermore, four out of eight ESBL-positive isolates had the blaTEM and blaVEB genes, two had blaTEM and blaSHV genes, and two carried blaTEM and blaPER genes simultaneously. In addition, the sequencing results manifested that blaTEM, blaVEB-1 and blaPER-1 of the isolates were 100% homogenized with the blaTEM-116, blaVEB-1 and blaPER-1 genes, respectively. However, the blaSHV gene was compatible with blaSHV-12 about 98%.

![The Analysis of P18 DNA Partial Sequence Identity on blaPER-1\
Subject: blaPER-1 (accession number: AY953376.2 in GenBank); Query: P18 sample. Its partial sequence shared 100% identity with AY953376.2.](jjm-08-01-13783-i001){#fig15157}

5. Discussion {#sec78298}
=============

*P. aeruginosa* is the most frequent pathogen causing nosocomial infections. Plasmid-mediated antibiotic resistance is commonplace in *P. aeruginosa* isolated from burn infected patients in different hospitals in Iran. Resistance of *P. aeruginosa* strains to the broad-spectrum cephalosporins may be mediated by ESBLs. The occurrence of MDR *P. aeruginosa* strains is growing in the world and limiting the therapeutic options ([@A13783R11]). Our investigation showed the resistance rate in the following order: CRO, CTX, IMI, ATM, CAZ, GM, PRL and CIP. The results showed that CIP (95.7%) and PRL (92.2%) were the most effective antipseudomonal agents.

In this study, the prevalence of ESBL-producing strains of *P. aeruginosa* was determined about 6.8%. While, in a study by Tavajjohi et al. in Kashan, Iran, it was 9.2%. Moreover, Woodford et al. in the UK and Lim et al. in Malaysia reported it as 3.7% and 4.2%, respectively ([@A13783R8], [@A13783R11], [@A13783R15]). However, the results of other investigators indicate high prevalence of ESBLs in *P. aeruginosa* strains, observed as about 28% in Thailand, 20.3% in India, 39.4% in the burn unit of Tehran, Iran, and 35.9% in the burn unit of northwest Pakistan patients. In the study by Shacheraghi et al. in Tehran, the frequency of the blaVEB-1 gene was 100% ([@A13783R4]). Mirsalehian et al. in Tehran observed that the frequency of blaPER-1 and blaVEB-1 were 49.25% and 31.34%, respectively ([@A13783R16]). However, in this study, the blaTEM gene frequency was 100% ([@A13783R16]-[@A13783R19]). The blaTEM gene in this study had 100% identity with blaTEM-116, which has been reported for the first time in Iran. blaTEM-116 is derived from blaTEM-1, which are different in two amino acids. Amino acid 84 in TEM-116 is Ile but in TEM-1 it is Val and amino acid 184 in TEM-116 is Val but in TEM-1 it is Ala. blaTEM-1 was the most frequent β-lactamase and conferred resistance to AMP, PRL, and cephalothin. TEM-116 had a spectrum that was expanded to CAZ, CTX, and ATM ([@A13783R20]), which are in agreement with our study.

Phenotypic detection of ESBLs by clavulanate in *P. aeruginosa* due to various reasons such as the presence of chromosomal AmpC, broad-spectrum oxacillinase, resistant to clavulanate or other resistance mechanisms such as low permeability of the membrane and efflux pumps, was more difficult than the *Enterobacteriaceae* and leads to false negative results ([@A13783R13]). In our study, this topic clearly indicated that despite of eight ESBL-positive phenotype isolates, 22 ESBL-negative phenotype isolates were the blaTEM genes. Therefore, molecular techniques such as PCR for detection of ESBLs seem to be necessary.
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